within Pharmacolibrary.Drugs.ATC.D;

model D10AX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.021666666666666667,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0011200000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0015,
    Tlag           = 720
  );

  annotation(Documentation(
    info ="<html><body><p>Dapsone is an antibacterial sulfone drug primarily used for the treatment of leprosy (Hansen's disease), dermatitis herpetiformis, and as a prophylactic treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients. Dapsone is still approved and in use today, especially in combination therapy for leprosy and for certain skin conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral 100 mg dose.</p><h4>References</h4><ol><li>J Zuidema, E S Hilbers-Modderman, F W Merkus,Clinical pharmacokinetics of dapsone.,Clinical pharmacokinetics,1986<a href='https://pubmed.ncbi.nlm.nih.gov/3530584/'>https://pubmed.ncbi.nlm.nih.gov/3530584/</a></li><li>Katie K Lovell, Rushan I Momin, Harneet Singh Sangha, Steven R Feldman, Rita O Pichardo,Dapsone Use in Dermatology.,American journal of clinical dermatology,2024<a href='https://pubmed.ncbi.nlm.nih.gov/39078587/'>https://pubmed.ncbi.nlm.nih.gov/39078587/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D10AX05;
